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1. Abstract 
 
Mitochondria are cellular organelles which contain mitochondrial DNA (MtDNA) in the form 
of an extranuclear genome. MtDNA can be present in 100s to thousands to copies per cell in 
the body depending on the bioenergetic requirements of the host cell. MtDNA encodes 
subunits of the electron transport chain and therefore is required to produce cellular energy 
in the form of ATP. However MtDNA can also act as an inflammatory molecule since it 
resembles bacterial DNA, resulting in activation of pathways leading to enhanced cytokine 
production and chronic inflammation. In the current chapter, we suggest that MtDNA 
mediated mechanisms that cause systemic mitochondrial dysfunction  are involved in many 
common dieases not traditionally recognised as mitochondrial disease, and we suggest that 
such  disorders could be considered as “acquired mitochondrial diseases”, distinct from 
primary and secondary mitochondrial disease.  Aquired mitochondrial diseases include 
cardiovascular and neurodegenerative disease as well as diabetic complications, and are 
associated with oxidative stress and sterile/chronic inflammation in their pathophysiology. 
We propose a mechanism of how systemic damage to MtDNA, mediated through oxidative 
stress, can cause inflammation and bioenergetic deficit. Some recent evidence of the 
proposed mechanism is provided for diabetic nephropathy, a complication of diabetes, 
which has not traditionally been regarded as a disease of mitochondrial dysfunction. 
According to the hypothesis proposed, it may be possible to use MtDNA levels in body fluids 
or cells to predict risk of aquired diseases of mitochondrial dysfunction, and to design novel 
therapies targetting the specific MtDNA mediated pathways.  
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2. Introduction 
Mitochondria are double-membrane bound organelles found in all human cells, with the 
exception of erythrocytes. Mitochondria are often described as the ‘powerhouses of the cell’ 
since they produce the majority of cellular energy  via oxidative phosphorylation (OXPHOS), 
a process  involving the transfer of electrons along a series of protein complexes in the inner 
mitochondrial membrane. The process of electron transport results in the production of some 
reactive oxygen species (ROS) (Boveris et al., 1972), which play an important role in normal 
intracellular signalling pathways (D’Autreaux and Toledano, 2007). In addition to cellular 
energy production, mitochondria play many other roles in the cell including homeostasis of 
cellular calcium, formation of iron-sulphur clusters and regulation of the intrinsic apoptosis 
pathway. Given their importance in maintaining normal cellular function, it is perhaps no 
surprise that mitochondria have become a focus of increased attention in terms of their 
potiential impact on the pathogenic mechanisms of human disease.   
It is believed that mitochondria originate from the integration of a eubacterium into a host 
cell , resulting in what we now call eukaryotic cells.  Through reductive evolution, the 
majoity of genes  were transfered from the eubacterial genome to the nucleus of the host, 
however a small DNA genome remained within the mitochondrial organelle. The 
mitochondrial genome (mtDNA) differs from the nuclear genome in terms of size, structure 
and mode of inheritance. With only 13 proteins encoded by mtDNA, the mitochondrion is 
under dual control relying on many other proteins encoded by the nuclear genome to 
function normally. Mutations in these genes can lead to mitochondrial dysfunction, 
manifesting at a cellular level in various ways, including OXPHOS deficiency, reduced mtDNA 
copy number or disruption of the mitochondrial network. The clinical symptoms associated 
with mitochondrial dysfunction fall under the umbrella term of ‘mitochondrial disease’, 
which encompasess a clinically and genetically diverse group of conditions with systemic 
effects on the body’s cell and organs (Figure 1).These are broadly categorised as either 
primary or secondary mitochondrial disease, however there is some overlap regarding the  
definition of these two main  groups. In addition, mitochondrial dysfunction has been 
postulated to play a  key role in many  other  common disease,  which were not traditionally 
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throught to be mitochondrial disease (Wallace, 1999). To distinguish these from primary or 
secondary mitochondrial disease, here we will refer to them as “acquired mitochondrial 
disease” and they are  the main topic of the current review (Table 1).  
 
Primary mitochondrial disease is usually  associated with inherited  mutations in  mtDNA or 
nuclear DNA which result in impaired OXPHOS (Niyazov et al., 2016). Pathogenic mutations 
can occur in genes encoding structural subunits of the OXPHOS system, such as the complex 
I subunits MT-ND1 in the mtDNA or NDUFS1 in the nuclear DNA. In addition, there are 
approximately 1500 nuclear genes encoding proteins indirectly affecting OXPHOS via 
processes like mtDNA replication, which have been implicated in a number of clinical 
syndromes. The prevalence of  primary adult mitochondrial disease due to nuclear and 
mitochondrial DNA mutations is estimated at 1 in 4300 (Gorman et al., 2015), although 
accurately estimating this is challenging due to the genetic and clinical heterogeneity of this 
group of diseases. Clinically, these conditions can affect any tissue with onset at any age, 
making diagnosis and management extremely challenging. Furthermore, there is little 
consistency between the clincial phenotype and the underlying mutation. For example, the 
m.3243A>G mutation is associated with a severe neurological condition termed MELAS 
(mitochondrial encephalopathy, lactic acidosis and stroke-like episodes), but can also 
manifest as a much milder CPEO (chronic external ophthalmoplegia) phenotype. Secondary 
mitochondrial disease arises due to mutations in “genes encoding neither function nor 
production of the OXPHOS proteins” (Niyazov et al., 2016). These mutations can be 
inherited,  as in the case of Friedreich’s ataxia where a mutation in the frataxin gene (FXN) 
leads to dysregulation of iron homeostasis (González-Cabo and Palau, 2013). A detailed 
description of primary and secondary mitochondrial disease  is beyond the scope of this 
chapter and the reader is referred to an excellent recent review by Gorman et al (2016).  
In addition to primary and seconday mitochondrial disease, it has been postulated that 
mitochondrial dysfunction plays a significant part in the pathogenesis of many common 
disorders including common metabolic disorders such as diabetes, cardiovascular disease, 
neurodegenrative diseases and cancers (Schon et al., 2012; Picard et al., 2016). A growing 
body of evidence implicates changes in MtDNA in cells organs and body fluids  in such diseases 
of aquired mitochndrial dysfunction, including prevalent and chronic health conditions 
including neurodegenerative disease, obesity, cardiovascular disease, diabetes and its 
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complications, fatty liver disease, and also include complications arising from drug toxicity 
(reviewed by Malik & Czajka, 2013, Malik, 2017). Furthermore, emerging evidence indicates 
that the development of mitochondrial dysfunction can also contribute to chronic 
inflammation and therefore may also be involved in a number of inflammatory pathways 
(Boyapati et al., 2017).   
In the current chapter, we consider the role of MtDNA in the mechanisms of pathogenesis in  
aquired mitochondrial disease. Accordingly, we suggest that  mitochondrial dysfunction plays 
a central role in many more dieases than traditionally recognised as mitochondrial disease, 
We propose that such  disorders could be described as putative “acquired mitochondrial 
diseases” (Table 1) and we propose a mechanism of how systemic damage to MtDNA, 
mediated through processes such as oxidative stress, and contributing to chronic 
inflammation and bioenergetic deficit, may be involved in the processes leading to aquired 
mitochondrial disease. To illustrate how the proposed mechanisms may contribute to 
common diseases,  we review some recent evidence using as an example one of the diseases 
shown in Table 1, namely diabetic nephropathy. Diabetic nephropathy has not traditionally 
been regarded as a disease of mitochondrial dysfunction.  
3. The Mitochondrial Genome 
In the eukaryotic cell, mitochondria are the only organelle, apart from the nucleus, to harbour 
a DNA genome. The nuclear genome comprises of linear DS DNA molecules, complexed with 
histone proteins in the form of chromosomes located within the nucleus , whereas the 
mitochondrial genome is a circular 16,569bp, double stranded molecule (Anderson et al., 
1981), present within the mitochondrial matrix as a protein-DNA complex  of approximately 
100nm length and  known as a nucleoid (Table 2). Nucleoids, located at the inner 
mitochondrial membrane, are estimated to contain between 1.4 to 3 copies of mtDNA (Kukat 
et al., 2011; Brown et al., 2011) which is complexed with several abundant proteins. The 
proteins within nuclaoids are involved in the mitochondrial replication and transcription 
machinery, for example the mitiochondrial transcription factor A (TFAM), mitochondrial DNA 
helicase (TWINKLE), single-stranded DNA binding protein (mtSSB) and mitochondrial DNA 
polymerase (Polγ) (Gilkerson et al., 2013). 
In total, the 16.5kb mtDNA contains 37 genes, encoding 22 transfer RNAs (mt-tRNAs), 13 
hydrophobic proteins involved in the OXPHOS system and two ribosomal RNAs (mt-rRNAs). 
Most of these genes are located on the outer, guanine-rich heavy strand, whereas the inner, 
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cysteine-rich light strand holds only 8 tRNA genes and one protein-encoding gene (MT-ND6) 
(Andrews et al., 1999). Unlike nuclear DNA, mtDNA is compact and contains no introns. One 
or two non-coding base-pairs separate genes, except in the case of MT-ATP6 and MT-ATP8, 
where there is a region of overlap between these two genes. There is only one non-coding 
region, known as the D-loop. This region, extending approximately 1kb in human mtDNA, 
contains the major control elements for mtDNA transcription and is the site of origin for heavy 
strand replication (Kasamatsu et al., 1971; Shadel and Clayton, 1997). 
In terms of genome copy numbers, there is a vast excess of MtDNA relative to nuclear DNA in 
the human body. With the exception of erythrocytes, human cells contain multiple 
mitochondria, each carrying  mtDNA. The number of mitochondria within a cell, and therefore 
the number of mtDNA copies, can vary depending upon the cellular energy requirements of 
the cell (Lightowlers et al., 1997). For example a cardiac muscle cell may have around 7000 
copies of mtDNA (Miller et al., 2003), a white blood cell may have less than a hundred (Selak 
et al., 2011) whereas oocytes may contain several hundred thousand copies (Shoubridge and 
Wei 2007). The number of mitochondria can also change in response to the cell’s physiological 
environment (Trinei et al., 2006), consequently, the amount of MtDNA found in different cell 
types varies depending on the mitochondrial content and bioenergetic requirements of the 
cell, as well as the physiological status of the cell. 
The inheritance of mtDNA follows a non-Mendelian pattern and is instead strictly maternally 
inherited (Giles et al., 1980), although there is one documented case of paternal inheritance 
of mtDNA with a deletion in MT-ND2 (Schwartz and Vissing, 2002), yet this has not been 
reported by others. Paternal mtDNA is thought to be eliminated by selective proteasomal 
degradation or autophagy post-fertilization, although degradation prior to fertilisation has 
also been reported (Luo et al., 2013). Mutations in mtDNA are passed from mother to child, 
however there is great variability in the heteroplasmy levels and phenotypic expression across 
generations (Taylor and Turnbull 2005). 
4. Mitochondrial DNA Content in different cells and organs  
Organs and cells in the body have differing levels of mitochondrial content, reflected by their 
MtDNA content. Mitochondrial content in different cells and organs varies depending on the 
bioenergetic requirements of the cells, with organs requiring high amounts of energy usually 
having a higher mitochondrial mass, therefore it follows that with altered mitochondrial mass 
there will be altered MtDNA content. Currently there is little consensus in the literature on 
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MtDNA content is different cells and organs. We have previosuly shown that in the mouse, 
the heart contains the highest MtDNA content followed by the kidney (Figure 2A, Malik et 
al., 2016), this observation correlates with earlier proteomic quantification of mitochondrial 
proteins which found the highest level of mitochondrial cytochrome C in the heart followed 
by the kidney (Figure 2B, Pagliarini et al., 2008). The observation of high mitochondrial 
content in heart and kidney is further supported by the assessment of metabolic rate of 
different organs where two reports of  very similar levels with heart and kidney showing the 
highest metabolic rates (Figure 2C, McClave and Snider 2001; Wang et al 2010).  
Oxidative stress and aquired mitochondrial dysfunction  
The key role of oxidative stress in the chronic disorders we designate as acquired 
mitochondrial disease has long been recognised and many therapeutic strategies are focused 
around the correction of redox impairment and scavenging of ROS (Halliwell and Gutteridge, 
2007). The process of energy production via OXPHOS uses oxygen and metabolic susbstates 
to produce energy in the form of ATP in mitochondria, and can directly result in oxidative 
stress in the cell, a condition in which the redox balance of the cell has shifted towards an 
oxidative state. It is largely accepted that oxidative stress is a common feature in many 
diseases including diabetes complications, cardiovascular disease, neurodegenerative 
disease, cancer, renal disease and others.  
OXPHOS involves the oxidation of nutrients by oxygen, mediated via the transfer of electrons 
through protein complexes known as the electron transport chain in the inner mitochondrial 
membrane. However, not all of the oxygen being used during OXPHOS is utilised to produce 
ATP, since ~1-3% is converted into free radicals, known as reactive oxygen species (ROS) 
(Halliwell and Gutteridge, 2007). ROS are highly reactive molecules with unpaired electrons 
and can oxidise and impair the function of cellular DNA, proteins and lipids. In the case of 
DNA, ROS damage can cause mutations, deletions and oxidation. Since MtDNA is found 
located close the the electron transport chain, it is more likely to incur ROS-induced damage 
than nuclear DNA.  
Under normal physiological conditions, most cells use cellular proteins such as glutathione 
peroxidise, catalase, and superoxide dismutase (Nordberg and Arnér, 2001) as antioxidants 
to sequester ROS by accepting electrons and becoming oxidised. These endogenous 
antioxidant proteins are highly abundant in cells and are recycled by donating their electrons 
to chains of acceptors such as reduced nicotinamide adenine dinucleotide phosphate 
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(NADPH) (Rydström, 2006).  However, in conditions of chronic ROS production, the cell’s ROS 
levels exceed their detoxification and cause a shift in the redox balance resulting in oxidative 
stress. Free radicals which escape the cells’ antioxidant response are highly reactive 
molecules which oxidise proteins, lipids and DNA molecules within the cell, leading to altered 
properties and cellular damage.  Many common drugs cause mitochondrial oxidative stress 
(reviewed by Mehta et al., 2008), and many common diseases such as diabetes and its 
complications, cancer, neurodegenerative disorders as well as ageing have been shown to 
have redox impairment (Halliwell and Gutteridge, 2007; Wallace, 1999; Ying, 2008). 
Mitochondria are directly affected by oxidative stress, which can impair their functioning at 
different levels, both by direct damage to MtDNA, mitochondrial lipids and proteins, and 
also indirectly by altering cellular signalling. Oxidative stress induced MtDNA damage is a 
central concept in the “free radical theory of ageing”, which proposes that oxidative stress 
and ROS directly lead to damage to MtDNA in the form of single mutations or deletions. 
Mutations and damage to MtDNA are clearly involved in ageing and several acquired 
diseases, although damage to MtDNA repair and replication errors are also likely to be 
involved in MtDNA damage rather than direct ROS induced damage.   
 Abnormal signalling has been shown to result in an adaptive response through enhanced 
production of mitochondria (Michel et al., 2012). We have shown that oxidative stress 
induced by hyperglycemia can cause an increase initial increase in MtDNA, however in cells 
with oxidative stress the increased MtDNA is not functional  as such cells show decreased 
viability, decreased cellular respiration, and decreased transcription of MtDNA (Czajka et al, 
2015). The effect of the shifted redox balance can also impact on mitophagy, the degradation 
and removal of damaged mitochondria. Reduced removal results in the accumulation of 
damaged mitochondria (Kim et al., 2007) as is the case for diabetes where blockage of the 
electron transport chain at complex III results in accumulation of excess ROS (Giacco and 
Brownlee, 2010; Newsholme et al., 2007).  As MtDNA is located close to the source of ROS 
production, the DNA itself can become damaged resulting in accumulation of deletions and 
mutations ( Croteau and Bohr, 1997).   
Theoretically, the maternally inherited mitochondrial genome in an individual should be the 
same in all cell types unless it has been damaged via mutations or deletions either before or 
after conception, in which case cells may exhibit heteroplasmy in their mitochondria (Taylor 
& Turnbull 2005). Since most cells contain many copies of MtDNA, ranging from 100s to 1000s 
9 
 
 
depending on their bioenergetic requirements, a small percentage of damaged MtDNA may 
not have much functional impact, and further MtDNA repair mechanisms and mitophagy may 
suffice to contain any impact of such damage. However, once a functional threshold is 
crossed, damage to MtDNA could result in metabolic perturbation in the tissue. Cells need 
sufficient energy supplies for cellular processes and a fully functional ETC is crucial especially 
in tissues with high energy requirements such as the heart, kidney and the brain. Damage to 
MtDNA, which encodes 37 genes, all crucial for mitochondrial function, in the form of 
acquired mutations, could lead to energy deficit by affecting the function of the ETC (Wallace 
1999). The inability to produce sufficient energy to carry out cellular processes is likely to have 
significant effects on cells, impairing cellular repair and growth and could lead to cell loss.  
5. Inflammation and aquired mitochondrial dysfunction 
 
It is increasingly being reported that MtDNA can directly cause inflammation in the body 
(reviewed by Malik & Czajka, 2013). Unlike eukaryotic nuclear DNA which is methylated, 
MtDNA resembles bacterial DNA in that it is largely un-methylated. Therefore, when MtDNA 
is  “out of place”, i.e not contained within the mitochondria, for example in damaged cells 
where MtDNA may leak into the cytosol or into circulation, it can be recognised by the 
immune system as foreign DNA. Therefore MtDNA can cause immune responses for example 
via the activation of the intracellular Toll like receptor 9 (TLR) 9 which normally recognises 
exogenous bacterial DNA released from pathogen. (Zhang et al 2010).   Activation of TLR9 by 
MtDNA can cause the activation of an inflammatory cascade via myeloid differentiation 
primary response gene 88 (MYD88) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and results in activation of cytokines such as TNFalpha leading to an 
inflammatory response which can persist in the absence of any exogenous infection 
(McCarthy et al., 2015). Indeed, MtDNA mediated inflammation may be the cause of 
phenomena described as “sterile inflammation”, where an enhanced inflammatory response 
occurs in the absence of infection  (Chen and Nunez, 2010).  
The diseases listed as “acquired mitochondrial diseases” (Table 1) share the feature of chronic 
or sterile inflammation since an enhanced inflammatory response ensues in the absence of 
any detectable pathogens or infection. There is overwhelming evidence showing a causal role 
of immune-inflammatory responses in cardiovascular disease where the presence of low 
grade inflammation in patients has been postulated to be causative of and to precede adverse 
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cardiovascular events (Welsh et al., 2017). There are many convincing studies using both 
animal models and human populations showing that in diabetes inflammation plays a 
significant role, and increased inflammatory markers are associated with diabetic 
nephropathy (Donate-Corea et al., 2014) and diabetic retinopathy (Semeraro et al., 2015). 
complications. Therefore it is tempting to speculate that inflammation present in these 
diseases may be mediated by MtDNA.  
As well as palying a potential role in chronic inflammatory responses, the release of large 
amounts of MtDNA can result in acute inflammatory responses with serious consequences. 
For example, blocking of MtDNA degradation in cardiac cells led to heart failure in a mouse 
model (Oka et al., 2012). Cell free MtDNA levels have been shown to strongly correlate with 
risk of mortality in intensive care units and in patients with sepsis. (Nakahira et al., 2013; 
Yamanouchi et al., 2013).  
6. Emerging evidence of MtDNA changes in a large number of chronic and other human 
diseases.  
MtDNA lends itself to rapid detection and quantification via methods such as qPCR and digital 
PCR, making it an attractive high-throughput biomarker. MtDNA levels can be measured in 
human clinical samples and disease associated changes can be detected in populations. There 
is widespread interest in using MtDNA as a biomarker in human populations and in the last 
decade, the evidence for reported alterations in MtDNA in body fluids, cells, or of human 
subjects in correlation with many diseases has grown rapidly and strongly supports the view 
that alterations in MtDNA levels are associated with many human diseases.  MtDNA levels 
have been measured in numerous types of human samples such as blood cells (e.g. 
lymphocytes, PBMCs), body fluids (urine, plasma, serum,saliva, cereborspinal fluid), , and in 
tissues or biopsies (normal and diseased e.g. cancer). Alterations in MtDNA levels have been 
described in numerous different types of cancers, cardiovascular disease, diabetes and its 
complications and others. A detailed description of this rapidly growing evidence base is 
beyond the scope of the current chapter (Reviewed by Malik and Czajka, 2013) however it is 
clear that many human diseases are associated with measureable changes in MtDNA. 
Furthermore, there is increasing evidence showing a link between patient drug response and 
circulating MtDNA levels showing that there is strong potential for the future use of MtDNA 
in the field of personalised medicine (Malik, 2017).  
7. Proposed mechanisms of Mitochondrial DNA mediated damage in aquired 
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mitochondrial disease.  
In 2013 we proposed a novel hypothesis stating that acquired damage to MtDNA, distinct 
from inherited genetic mitochondrial disease, can result in mitochondrial dysfunction in a 
specific pathway involving an early increase in MtDNA levels (Malik and Czajka 2013; Czajka 
et al., 2015). According to this hypothesis, changes in MtDNA may impact on cellular health 
via two distinct but interconnected processes: (a) Bio-energetic deficit in cells caused by 
mutations in MtDNA leading to a defective electron transport chain resulting in cellular 
damage, and release of damaged MtDNA into circulation (b) Accumulation of damaged 
MtDNA in the cytosol (instead of within mitochondria) and of cell free MtDNA in circulation 
could lead to chronic inflammation. Therefore, this hypothesis predicts an early adaptive 
increase in MtDNA in response to oxidative stress, and subsequently a decrease in levels of 
MtDNA as well as damage to MtDNA, followed by increased inflammation and reduced 
bioenergetic capacity (see figure 3).  In order to detect the changes predicted by this 
hypothesis, we have used experimental model systems and clincial samples for the disease 
diabetic nephropathy.  
Diabetes results in increased risk of numerous other complications which affect major organs, 
including eyes (retinopathy), heart (diabetic cardiomyopathy), blood vessel (peripheral 
vascular disease) and brain (dementia) (Figure 1) and therefore resembles genetic forms of 
mitochondrial disease. Diabetic nephropathy is a kidney disease which affects approximately 
30% of patients with diabetes. The disease, detected using microalbuminuria, the appearance 
of protein in the urine, develops over a period of clinical silence and can lead to gradual loss 
of renal function resulting in end stage renal failure. With the epidemic rise in the incidence 
of diabetes currently affecting more 350 million people worldwide, more than 100 million 
people are at risk of DN and approximately 30% of these are likely to progress to end stage 
renal failure despite therapy .  Kidneys are organs requiring large amounts of energy in form 
of ATP due to the re-absorption processes and although their mass account of less than 1% 
of total body mass, they use almost 10% of the body’s oxygen which is utilized in cellular 
respiration via OXPHOS, and therefore they are rich in mitochodnrial content and MtDNA. We 
used human primary renal glomerular mesangial cells (HMCs) as well as patient samples to 
detect the changes predicted by the hypothesis described in Figure 3 (Malik and Czajka, 2013; 
Czajka and Malik, 2016). We showed that when  HMCs are grown in diabetic conditions, the 
high glucose leads to increased ROS and at the same time we observed more than 200% 
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increase in cellular MtDNA (Figure 4A), however this MtDNA was damaged (Figure 4B) , and 
moreover continued growth in high glucose led to damaged cellular respiration in parallel 
with increased ROS (Figure 4E). We also found evidence of similar changes in blood samples 
taken from diabetes patients with and without diabetic kidney disease (See Czajka et al., 
2015) and in patients with diabetic retinopathy, where circulating MtDNA changes correlated 
with inflammation (Malik et al., 2015). Specific MtDNA mutations can lead to diabetes and 
kidney disease in patients with mitochondrial genetic disease (Wallace et al 1999; Mazzaccara 
et al 2012; Seidowsky et al 2013; D’Aco et al 2013). These genetic forms of diabetes and kidney 
disease support our hypothesis as they show that MtDNA damage can cause these specific 
pathologies.  
 
8. Concluding remarks  
In the current chapter we have described potential mechanisms by which changes in MtDNA 
levels may mediate mechanisms of disease common diseases which we have termed acquired 
mitochondrial diseases. The proposed mechanisms centre around two attributes of MtDNA. 
Firstly, MtDNA encodes subunits needed for a functional electron transport chain in order to 
make cellular energy via OXPHOS, and secondly MtDNA is a potentially pathogenic molecule 
as it can elicit  inflammatory responses in cells through its resemblance to bacterial or foreign 
DNA. Therefore, in diseases of oxidative stress, damage to MtDNA, initially causes a 
maladaptive response in the form of increased cellular MtDNA levels, and subsequently cause 
a bioenergetic deficit through imparied OXPHOS. Lack of cellular energy in cells results in 
release of damaged MtDNA which then would cause an inflammatory response. In diseases 
we describe as aquired mitochondrial diseases, both oxidative stress and inflammation have 
been strongly implicated. However targeted therapies to correct redox impairment and/or 
chronic inflammation have had limited clinical success. It is possible that a more targeted 
approach, which takes into account the potential timeline of events with early oxidative stress 
related changes and importantly, their impact on MtDNA, as well as  later inflammatory event 
may be required. The goal therefore is to identify methods for early detection of 
mitochondrial dysfunction to allow intervetion and treatment before irreversible damage to 
mitochondria in different regions of the body can lead to disease (Figure 5). Ideally, a 
biomarker which can detect mitochondrial dysfunction at an early stage is required. We 
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suggest the MtDNA has the potential to be such a biomakrer.  
Evidence for dysregulated MtDNA levels in numerous diseases continues to grow at a fast 
pace. Since the year 2000, almost 800 papers per annum have been  published on some aspect 
of human MtDNA, and a large percentage of these relate to altered MtDNA in chronic disease 
in human body fluids or cells. Interestingly, our data suggests that early changes in MtDNA, 
caused by altered redox balance in the cell, may provide a predictive biomarker (Figure 4), 
since we found changes in MtDNA were detectable ealry, and preceded bioenergetic deficit.  
 Therefore one potential way to identify the stage of events is to use non invasive methods to 
measure MtDNA content in humkan subjects. However, although the wider availability of 
qPCR as a methodology has led to a substantial increase in publications reporting changes in 
MtDNA content in human body fluids and tissues, methodological issues remain. Protocols 
for accurately quantifying MtDNA in small volumes of body fluids remain variable and affected 
by problems. Such methodology issues have hindered the successful use of MtDNA as a 
biomarker and led to conflicting and unreproducible findings in many cases. Of particular note 
in this regard is the presence of nuclear mitochondrial DNA segments (NUMTs) in the nuclear 
genome which can skew data by co-amplifying nuclear genes when MtDNA levels are being 
assessed. In addition, assays currently in use seldom distinguish between cell free and cellular 
MtDNA, the former is of importance as it may be an indicator of inflammation, and the latter 
is important as it may be an indicator of bioenergetic deficit in the cell. Therefore there is a 
growing need to accurately measure MtDNA levels in peripheral blood, compartmentalised 
as PMBCs for cellular and plasma for cell-free, as well as in urine, compartmentalised as 
urinary pellet for cellular debris and cell free urinary supernatant, or other body fluids, such 
as  saliva, semen, or cerebrospinal fluid.  The field of MtDNA may hold the potential for the 
elucidation of many more diseases than traditionally thought of as mitochondrial genetic 
disease.  
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Table 1: Primary, secondary and acquired mitochondrial disease   
 
Group and 
definition  
Definition  Example: Genes if known: Effects References  
Primary 
mitochondrial 
disease  
Mostly inherited 
mutations which 
result in impaired 
OXPHOS 
Leigh Syndrome: Progressive neurological disorder with infantile onset > 75 
nDNA and mtDNA genes implicated. Affects thalamus, basal ganglia and brain 
stem.  
Gorman et al, 2016 
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes 
(MELAS): mtDNA mutation m.3243A>G (MT-TL1) accounts for 80% cases. 
Affect many systems including brain, heart, eyes, ears, stature, balance.   
Leber Hereditary Optic Neuropathy (LHON) – predominantly caused by three 
mt-DNA mutations in OXPHOS genes.  Organ-specific condition associated 
with vision loss. 
Secondary 
mitochondrial 
disease  
Mostly inherited 
mutations which 
affect mitochondrial 
function (not in 
genes encoding 
OXPHOS) 
Friedreich’s Ataxia - Neurodegenerative condition caused by mutation in the 
Frataxin gene resulting in impaired iron metabolism. Cerebellar ataxia and 
cardiomyopathy are common symptoms.  
González-Cabo & 
Palau, 2013 
Charcot-Marie-Tooth type 2A – Peripheral neuropathy associated with 
mutation in MFN2 gene involved in mitochondrial fusion dynamics.  
Cartoni & Martinou, 
2009  
Wilson’s disease – Mutations in ATP7B cause abnormal copper metabolism, 
resulting in a multifactorial condition primarily affecting the liver. 
Wu et al, 2015 
Acquired 
mitochondrial 
disease  
Somatic 
mutations/deletions 
in MtDNA caused by 
environmental 
factors (e.g oxidative 
stress) affecting 
specific target tissues  
Neurodegenerative Disease (e.g. non-familial forms of Alzheimer’s disease1, 
Parkinson’s disease2, multiple sclerosis and others)  
1Wilkins & Swerdlow, 
2016; 2Bose & Beal, 
2016 
Cancer (e.g. colorectal cancer, breast cancer and others) Chen et al, 2016 
Cardiovascular disease (e.g. heart failure, ischaemic heart disease) Murphy et al, 2016 
Diabetes1 and its complications (Diabetic nephropathy2, retinopathy, and 
others) 
1Morrow et al, 2017; 
2Higgins & Coughlan, 
2013 
Drug induced toxicity1 (e.g HIV treatment induced toxicity2) 1 Walker, 2008; 
2Gardner et al, 2013 
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Table 2 – Comparison of Human Mitochondrial and Nuclear DNA Genomes  
 
 
  Mitochondrial DNA Nuclear DNA 
Structure  
 
 
Size (nt) 16,569 ~30,000,000,000  
Major Function  Information storage 
DNA replication and 
transcription, signalling  
Information storage 
DNA replication and 
transcription  
Organisation  Double-stranded circular DNA 
molecule complexed with 
TFAM 
Double-stranded duplex linear 
DNA molecules (chromosomes) 
complexed with histones to 
form chromatin 
Genetic code  Different use of start and stop 
codons 
Universal 
Replication  Bidirectional from a single 
origin of replication 
Numerous origins of replication  
Transcription  Poly-cistronic mRNAs from 2 
promoters 
Highly regulated and mostly 
individual mRNA transcription 
from thousands of individual 
promoters 
Introns/exons  No introns, very few non-
coding regions, contiguous and 
overlapping  
Contain introns and large 
stretches of non-coding regions  
Inheritance  Maternal  Bi-parental  
Replication  Independent of the cell cycle Dependent on the cell cycle  
Number of copies per 
cell 
10s to many 1000s –variable 
and can change in response to 
physiological stimuli 
2 (1 in the case of the sex 
chromosomes)-fixed 
Methylation Resembles bacterial DNA (less 
methylated) 
Methylated 
Sequence identity  Contains very few regions 
which are unique (>90% is 
duplicated in the nuclear 
genome)  
Contains variable regions 
known as NUMTs (nuclear 
mitochondrial DNA segments) 
which are identical to MtDNA 
scattered across most 
chromosomes  
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Figure 1. Systemic impact of mitochondrial disease. Common symptoms of mitochondrial disease are shown 
alongside examples of primary1, secondary2 and acquired3 mitochondrial diseases. Abbrviations: MELAS = 
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes; CPEO = Chronic Progressive 
Ophthalmoplegia; LHON = Leber’s Hereditary Optic Neuropathy; GI = gastrointestinal.  
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Figure 2: Mitochondrial content in different tissues. A) Mitochondrial DNA copy number in mouse tissue (Malik 
et al., 2016). B) Mitochondrial content, represented by cytochrome c levels, in mouse tissues (Pagliarini et al., 
2008). C) Metabolic rates of human tissues and organs (McClave and Snider, 2001; Wang et al., 2010).  
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Figure 3: Proposed mechanism of mitochondrial DNA mediated damage in acquired mitochondrial diseases.  
A trigger such as hyperglycemia leads to increased intracellular reactive oxygen species (ROS). Under normal 
conditions, the cell’s endogenous antioxidant response recovers the redox balance by scavenging the ROS. 
However, under conditions of chronic ROS, the cell’s antioxidant response is overwhelmed resulting in oxidative 
stress. Increased intracellular ROS leads to increased mitochondrial biogenesis, an adaptive response, which can 
be detected by measuring Mt/N. Over time the oxidative stress would cause damage to mitochondrial 
membranes, proteins and DNA leading to mitochondrial dysfunction. Accumulation of damaged MtDNA would 
lead to an inflammatory response as MtDNA is un-methylated and resembles bacterial DNA. According to this 
hypothesis changes in Mt/N would precede mitochondrial dysfunction. Figure adapted from Malik & Czajka 
2013.  
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Figure 4: Changes in cellular MtDNA precede metabolic dysfunction in conditions of oxidative stress. Growth 
of human mesangial cells (HMCs) in high glucose led to a significant increase in cellular MtDNA within 24 hours, 
(A) after 4 days (n=12, P<0.001), however the MtDNA was damaged as illustrated by reduced amplification of 
an MtDNA 8.6kb fragment (B). Cells showed normal bio-energetic profile at 4 days (C), however after 8 days, 
maximal respiration and reserve capacity were significantly reduced in hyperglycemia cells but unaffected in 
normoglycmeic cells (D, E). See Czajka et al., 2015 for the full data.   
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Figure 5: Early detection of mitochondrial dysfunction to prevent chronic disease. Environmental/lifestyles 
triggers such as high fat and/or glucose or drugs can result in oxidative stress and altered signaling which in turn 
damages mitochondria in organs (e.g. kidney, heart, liver), cells (blood cells, adipocytes), and blood vessels, the 
damage may take decades to manifest itself and cause pathology. Identification of biomarkers for the early 
detection of the metabolic and bioenergetic changes associated with these pathologies could allow intervention 
and prevention of irreversible bioenergetic dysfunction.  
 
 
